Crispr Therapeutics AG (1CG)

40.0000
0.0000(0.00%)
  • Volume:
    0
  • Bid/Ask:
    41.0000/41.2000
  • Day's Range:
    39.4000 - 40.0000
  • Type:Equity
  • Market:Germany
  • ISIN:CH0334081137
  • WKN:A2AT0Z

1CG Overview

Prev. Close
39.6
Day's Range
39.4-40
Revenue
-
Open
39.4
52 wk Range
0-0
EPS
-
Volume
0
Market Cap
6.44B
Dividend (Yield)
N/A
(N/A)
Average Vol. (3m)
-
P/E Ratio
9.28
Beta
-
1-Year Change
0%
Shares Outstanding
76,201,185
Next Earnings Date
-
What is your sentiment on CRISPR Therapeutics AG?
or
Market is currently closed. Voting is open during market hours.

CRISPR Therapeutics AG News

CRISPR Therapeutics AG Analysis

Technical Summary

Type
5 Min
15 Min
Hourly
Daily
Monthly
Moving Averages
Technical Indicators
Summary

CRISPR Therapeutics AG Company Profile

CRISPR Therapeutics AG Company Profile

Employees
410

CRISPR Therapeutics AG is a Switzerland-based gene-editing company. It focuses on the development of transformative gene-based medicines for serious diseases. The Company develops its products using Clustered Regularly Interspaced Short Palindromic Repeats (CRISPR)/Cas9 gene-editing platform, which allows for precise directed changes to genomic deoxyribonucleic acid (DNA). The Company has a portfolio of therapeutic programs in a range of disease areas, including hemoglobinopathies, oncology, regenerative medicine and rare diseases. Its lead product candidate is CTX001, an ex vivo CRISPR gene-edited therapy for treating patients suffering from transfusion-dependent beta thalassemia or severe sickle cell disease in which a patient’s hematopoietic stem cells are engineered to produce high levels of fetal hemoglobin in red blood cells. The Company has business operations in London and the United Kingdom, as well as research and development operations in the United States.

Read More
  • Ouch
    0
    • In few weaks 120
      0
      • why are you so sure Mr. John Doe ? please ?
        0
      • Possible. 102 is more likely. If it does approach 120, breaking 124 resistance will be a signifant upside challenge.
        0
      • in 4 weeks 85
        1
    • ouch. well since we're here.. i might as well average down
      0
      • median bollinger band is broken on monthly TF... waiting the end of october...
        1
        • 97 usd  is a good entry point...
          3
          • a classic Cathy wood collapse
            7
            • how do you actually buy shares i have a buy sell window open but its an ad i wanna actually buy a stock not be sent to yet another bs broker app
              0
              • Check if you Bank can help you out
                0
              • Open and fund a brokerage account. There are many options.
                0
            • wow
              0
              • Beat on earnings!! Largly
                0
                • Problem with this one is you're gonna need to wait a literal decade for it to be viable, regardless of studies/tests.
                  0
                  • true
                    0
                  • I think in a normal world… Definitely. My opinion, it right around the corner.
                    0
                • total bubble of cathie wollod pump
                  3
                  • CRSP and AIRI are Good stockAIRI will go up to X3
                    0
                    • keep on dropping...
                      0
                      • good entry point is around 80
                        2
                        • keep dropping, want to get back in
                          0
                          • 206 by Oct
                            2
                            • That would be acceptable.
                              0
                          • Last weekend, Intellia Therapeutics and Regeneron announced first-ever clinical data that support the safety and efficacy of in vivo CRISPR genome editing in humans. We summarise the findings here.
                            0
                            • ride it to new highs
                              1
                              • Alert: Crispr Therapeutics will acquire AGTC before end of FY2021 as a strategy to get into the ophthalmology space. Load up now & Stay tuned
                                0
                                • ok, thanks
                                  0
                                • Thank you, but may we know your source, please?
                                  0
                                • What proof or source do you have that these facts have changed? See quote:  Gene therapy developer AGTC lost nearly half its market cap Thursday morning after Biogen exited a collaboration agreement on the heels of a big clinical failure. Interim six-month data on one of AGTC's investigational therapies showed it was generally safe but ineffective at treating a rare eye disorder known as X-linked retinoschisis (XLRS). The company plans to complete patient monitoring activities on the XLRS program but will not develop it further.
                                  0
                              • Held the dip, looks great
                                0
                                • i think that someone knew the news about intellia on friday already and then bought Crispr quickly.
                                  0
                                  • i thought the same.. lucky enough it was good news
                                    0
                                • ouch...shorts are about to get crushed
                                  0
                                  • It will most likely go higher on monday due to good results from Intellia.
                                    0
                                    • Any reason why it's up over 5% today?
                                      0
                                      • lander.gates.fauci
                                        0
                                        Disclaimer: Fusion Media would like to remind you that the data contained in this website is not necessarily real-time nor accurate. All derived (stocks, indexes, futures), cryptocurrencies, and Forex prices are not provided by exchanges but rather by market makers, and so prices may not be accurate and may differ from the actual market price, meaning prices are indicative and not appropriate for trading purposes. Therefore Fusion Media doesn't bear any responsibility for any trading losses you might incur as a result of using this data.
                                        Fusion Media or anyone involved with Fusion Media will not accept any liability for loss or damage as a result of reliance on the information including data, quotes, charts and buy/sell signals contained within this website. Please be fully informed regarding the risks and costs associated with trading the financial markets, it is one of the riskiest investment forms possible.